HomeCompareHARP vs PM

HARP vs PM: Dividend Comparison 2026

HARP yields 8.69% · PM yields 3.49%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PM wins by $14.1K in total portfolio value
10 years
HARP
HARP
● Live price
8.69%
Share price
$23.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$35.6K
Annual income
$1,504.59
Full HARP calculator →
PM
Philip Morris International
● Live price
3.49%
Share price
$164.83
Annual div
$5.76
5Y div CAGR
17.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$2,502.61
Full PM calculator →

Portfolio growth — HARP vs PM

📍 PM pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHARPPM
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HARP + PM cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HARP pays
PM pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HARP
Annual income on $10K today (after 15% tax)
$738.81/yr
After 10yr DRIP, annual income (after tax)
$1,278.90/yr
PM
Annual income on $10K today (after 15% tax)
$297.03/yr
After 10yr DRIP, annual income (after tax)
$2,127.22/yr
At 15% tax rate, PM beats the other by $848.32/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HARP + PM for your $10,000?

HARP: 50%PM: 50%
100% PM50/50100% HARP
Portfolio after 10yr
$42.6K
Annual income
$2,003.60/yr
Blended yield
4.70%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PM right now

HARP
Analyst Ratings
7
Buy
2
Hold
Consensus: Buy
Price Target
$700.00
+2942.2% upside vs current
Range: $700.00 — $700.00
Altman Z
0.4
Piotroski
2/9
PM
Analyst Ratings
17
Buy
7
Hold
1
Sell
Consensus: Buy
Price Target
$194.30
+17.9% upside vs current
Range: $180.00 — $205.00
Altman Z
4.0
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HARP buys
0
PM buys
0
No recent congressional trades found for HARP or PM in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHARPPM
Forward yield8.69%3.49%
Annual dividend / share$2.00$5.76
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%17.2%
Portfolio after 10y$35.6K$49.6K
Annual income after 10y$1,504.59$2,502.61
Total dividends collected$11.9K$11.8K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy
Analyst price target$700.00$194.30

Year-by-year: HARP vs PM ($10,000, DRIP)

YearHARP PortfolioHARP Income/yrPM PortfolioPM Income/yrGap
1← crossover$11,569$869.19$11,650$409.56$81.00PM
2$13,319$939.79$13,592$497.49$273.00PM
3$15,262$1,011.14$15,882$605.21$620.00PM
4$17,414$1,082.88$18,589$737.41$1.2KPM
5$19,787$1,154.69$21,794$899.94$2.0KPM
6$22,399$1,226.25$25,597$1,100.16$3.2KPM
7$25,264$1,297.27$30,118$1,347.30$4.9KPM
8$28,400$1,367.49$35,505$1,652.97$7.1KPM
9$31,824$1,436.67$41,940$2,031.88$10.1KPM
10$35,557$1,504.59$49,643$2,502.61$14.1KPM

HARP vs PM: Complete Analysis 2026

HARPStock

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian and pancreatic cancer, and other mesothelin-expressing tumors. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Full HARP Calculator →

PMConsumer Staples

Philip Morris International Inc. operates as a tobacco company working to delivers a smoke-free future and evolving portfolio for the long-term to include products outside of the tobacco and nicotine sector. The company's product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, vapor, and oral nicotine products that are sold in markets outside the United States. The company offers its smoke-free products under the HEETS, HEETS Creations, HEETS Dimensions, HEETS Marlboro, HEETS FROM MARLBORO, Marlboro Dimensions, Marlboro HeatSticks, Parliament HeatSticks, and TEREA brands, as well as the KT&G-licensed brands, Fiit, and Miix. It also sells its products under the Marlboro, Parliament, Bond Street, Chesterfield, L&M, Lark, and Philip Morris brands. In addition, the company owns various cigarette brands, such as Dji Sam Soe, Sampoerna A, and Sampoerna U in Indonesia; and Fortune and Jackpot in the Philippines. The company sells its smoke-free products in 71 markets. Philip Morris International Inc. was incorporated in 1987 and is headquartered in New York, New York.

Full PM Calculator →
📬

Get this HARP vs PM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HARP vs SCHDHARP vs JEPIHARP vs OHARP vs KOHARP vs MAINHARP vs MOHARP vs BTIHARP vs PEP

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.